3,219
Views
18
CrossRef citations to date
0
Altmetric
Editorials

Why, why, why de-lupus (does so badly in clinical trials)

&
Pages 95-98 | Received 14 Sep 2015, Accepted 21 Oct 2015, Published online: 19 Jan 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Jacqueline L. Paredes & Timothy B. Niewold. (2020) Type I interferon antagonists in clinical development for lupus. Expert Opinion on Investigational Drugs 29:9, pages 1025-1041.
Read now
Farhana Muhammad Yusoff, Kah Keng Wong & Norhanani Mohd Redzwan. (2020) Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity 53:1, pages 8-20.
Read now
Zdenka Hruskova & Vladimir Tesar. (2018) Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opinion on Biological Therapy 18:9, pages 989-996.
Read now
Pedro Mota, Venkat Reddy & David Isenberg. (2017) Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expert Review of Clinical Immunology 13:7, pages 667-676.
Read now
Vladimir Tesar & Zdenka Hruskova. (2017) Belimumab in the management of systemic lupus erythematosus – an update. Expert Opinion on Biological Therapy 17:7, pages 901-908.
Read now
Massimo Radin, Irene Cecchi, Karen Schreiber, Simone Baldovino, Daniela Rossi, Elisa Menegatti, Dario Roccatello & Savino Sciascia. (2017) Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. Expert Opinion on Orphan Drugs 5:1, pages 55-69.
Read now

Articles from other publishers (12)

Joan T. Merrill, Joel Guthridge, Miles Smith, Joshua June, Fotios Koumpouras, Wambui Machua, Anca Askanase, Arezou Khosroshahi, Saira Z. Sheikh, Gaurav Rathi, Bart Burington, Paul Foster, Mark Matijevic, Sujata Arora, Xiaodong Wang, Minggeng Gao, Stephen Wax, Judith A. James & Debra J. Zack. (2023) Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial . Arthritis & Rheumatology 75:12, pages 2185-2194.
Crossref
Chandra Mohan, Ting Zhang & Chaim Putterman. (2023) Pathogenic cellular and molecular mediators in lupus nephritis. Nature Reviews Nephrology 19:8, pages 491-508.
Crossref
Fulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, Claudia Ciancarella, Giulio Dolcini, Angelica Gattamelata, Cristiano Alessandri & Fabrizio Conti. (2023) Application of Machine Learning Models in Systemic Lupus Erythematosus. International Journal of Molecular Sciences 24:5, pages 4514.
Crossref
Maud Tusseau & Alexandre Belot. (2022) “P2RY8-son” break of tolerance promotes SLE. Journal of Experimental Medicine 219:1.
Crossref
George A. Robinson, Junjie Peng, Ines Pineda-Torra, Coziana Ciurtin & Elizabeth C. Jury. (2021) Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk. Metabolites 12:1, pages 3.
Crossref
Rishi R. Goel, Sergei V. Kotenko & Mariana J. Kaplan. (2021) Interferon lambda in inflammation and autoimmune rheumatic diseases. Nature Reviews Rheumatology 17:6, pages 349-362.
Crossref
George A. Robinson, Kirsty E. Waddington, Leda Coelewij, Junjie Peng, Meena Naja, Chris Wincup, Anna Radziszewska, Hannah Peckham, David A. Isenberg, Yiannis Ioannou, Coziana Ciurtin, Ines Pineda-Torra & Elizabeth C. Jury. (2021) Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. EBioMedicine 65, pages 103243.
Crossref
Konstantinos Tselios, Laura Wakani, Dafna D Gladman, Jiandong Su & Murray B Urowitz. (2021) Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. Rheumatology 60:1, pages 73-80.
Crossref
S. K. Solovyev, E. A. Aseeva, T. V. Popkova, A. M. Lila, V. I. Mazurov & E. L. Nasonov. (2020) Systemic lupus erythematosus: new horizons for diagnosis and therapy. Rheumatology Science and Practice 58:1, pages 5-14.
Crossref
E L. Nasonov, T. V. Beketova, L. P. Ananyeva, V. I. Vasilyev, S. K. Solovyev & A. S. Avdeeva. (2019) PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice 57, pages 1-40.
Crossref
Alexis Jones, Patrick Muller, Caroline J Dore, Felicia Ikeji, Emilia Caverly, Kashfia Chowdhury, David A Isenberg, Caroline Gordon & Michael R Ehrenstein. (2019) Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open 9:12, pages e032569.
Crossref
Robert I. Fox & Carla M. Fox. (2016) Sj?gren Syndrome. Rheumatic Disease Clinics of North America 42:3, pages 519-530.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.